Presepsin as a Novel Biomarker in predicting In‐hospital Mortality in Patients With COVID‐19 Pneumonia

Assal, Hebatallah Hany; Abdelrahman, Safaa M.; Abdelbasset, Maha AlyAlden; Abdelaziz, M.; Sabry, Irene M.; Shaban, Marwa M.

doi:10.1016/j.ijid.2022.02.054

Cited by 18 publications

(19 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a study by Kocyigit et al [27], PSS levels were significantly increased in the severe group compared with the mild and moderate groups of patients with COVID-19. In accordance with our findings, previous studies found that the PSS levels were significantly elevated in nonsurvivors than in survivors [16,28]. Park et al [16] demonstrated that the AUC value of PSS for predicting 30-day mortality was 0.90 and that it was not significantly different from that of PCT.…”

Section: Discussionsupporting

confidence: 92%

Predictive Values of Procalcitonin and Presepsin for Acute Kidney Injury and 30-Day Hospital Mortality in Patients with COVID-19

et al. 2022

View full text Add to dashboard Cite

Background and Objectives: Acute kidney injury (AKI) is a common complication in patients with coronavirus disease 2019 (COVID-19). We investigated the values of procalcitonin (PCT) and presepsin (PSS) for predicting AKI and 30-day hospital mortality in patients with COVID-19. Materials and Methods: We retrospectively evaluated 151 patients with COVID-19 who were admitted to the hospital via the emergency department. The diagnosis of AKI was based on the Kidney Disease: Improving Global Outcomes clinical practice guidelines. Results: The median patient age was 77 years, and 86 patients (57%) were male. Fifty-six patients (37.1%) developed AKI, and 19 patients (12.6%) died within 30 days of hospital admission. PCT and PSS levels were significantly higher in patients with AKI and non-survivors. The cutoff values of PCT levels for predicting AKI and mortality were 2.26 ng/mL (sensitivity, 64.3%; specificity, 89.5%) and 2.67 ng/mL (sensitivity, 68.4%; specificity, 77.3%), respectively. The cutoff values of PSS levels for predicting AKI and mortality were 572 pg/mL (sensitivity, 66.0%; specificity, 69.1%) and 865 pg/mL (sensitivity, 84.6%; specificity, 76.0%), respectively. Conclusion: PCT and PSS are valuable biomarkers for predicting AKI and 30-day hospital mortality in patients with COVID-19.

show abstract

Section: Discussionsupporting

confidence: 92%

Predictive Values of Procalcitonin and Presepsin for Acute Kidney Injury and 30-Day Hospital Mortality in Patients with COVID-19

et al. 2022

View full text Add to dashboard Cite

show abstract

“…В качестве раннего прогностического маркера SARS-CoV-2-ассоциированной ТП большим потенциалом обладает белок пресепсин [32][33][34][35][36][37][38]. Однако область применения пресепсина как прогностического фактора в респираторной медицине ограничена именно ТП [39].…”

Section: маркеры иммунного ответа организмаunclassified

“…Пресепсин является регуляторным фактором, который модулирует иммунные ответы, взаимодействуя с Т-и В-лимфоцитами. Выявлена значительная корреляция между уровнем пресепсина в сыворотке крови и уровнями прокальцитонина, СРБ и лактата, индексом тяжести пневмонии и оценкой риска системной дисфункции (шкала быстрой оценки органной недостаточности, связанной с сепсисом (quick Sequential Organ Failure Assessment -qSOFA)) [37,40]. Уже при поступлении в стационар на основании показателя пресепсина в крови можно прогнозировать обострение ОРДС и клинический исход пневмонии, что позволяет врачам не только выявлять пациентов с высоким риском, нуждающихся в кислородной поддержке и интенсивной терапии, но и определять стратегию лечения [33,36,41,42].…”

Section: маркеры иммунного ответа организмаunclassified

Potential predictors of severe course and outcome of community-acquired pneumonia

Volchkova¹,

Titova

Кузубова

et al. 2023

Pulʹmonologiâ (Mosk.)

View full text Add to dashboard Cite

Severe pneumonia is a condition with a high risk of death and mandatory hospitalization in the intensive care unit. The incidence of severe pneumonia has increased dramatically during the pandemic of new coronavirus infection. Timely diagnosis and early initiation of adequate treatment of severe pneumonia are crucial for improving survival of critically ill patients.The aim of this review was to analyze published scientific research on molecular markers that allow to objectively assess the severity of pneumonia and to determine treatment tactics based on the predicted outcome upon admission to the hospital. A systematic search was conducted in the electronic databases PubMed, Medline, Web of Science for the period 2019 - 2022.Conclusion. The review focuses on the prognostic role of a number of markers of immune response, vascular transformation, as well as angiotensin II and angiotensin converting enzyme-2. Further prospective studies of potential predictors of severe pneumonia will enable using marker molecules in a comprehensive clinical and laboratory diagnosis for early prediction of the hospitalized patient’s condition and expected outcome.

show abstract

“…Several biomarkers such as C-reactive protein (CRP), serum ferritin, D-dimer, and interleukin-6 (IL-6) have been studied for prognostic assessment of patients with COVID-19 pneumonia or simply for patient management ( 3 ). New biomarkers such as presepsin as a soluble CD14 subtype in sepsis patients have been continuously included ( 4 ).…”

Section: Introductionmentioning

confidence: 99%

“…The role of cytokines and chemokines has been associated with disease severity and clinical COVID-19 outcomes during all pandemic, suggesting that these molecules are the most promising biomarkers for patient management. Some inflammatory biomarkers have been reported to be significantly associated with an increased risk of developing severe COVID-19, such as procalcitonin (PCT), serum ferritin, CRP, IL-6, or erythrocyte sedimentation rate (ESR) ( 4 ). In addition, technologies combining flow and mass cytometry have improved multiple single-cell immune profiling in COVID-19 patients by revealing changes in both innate and adaptive immune cell subpopulations and their correlation with disease severity.…”

Section: Introductionmentioning

confidence: 99%

Relevance of TMPRSS2, CD163/CD206, and CD33 in clinical severity stratification of COVID-19

et al. 2023

View full text Add to dashboard Cite

BackgroundApproximately 13.8% and 6.1% of coronavirus disease 2019 (COVID-19) patients require hospitalization and sometimes intensive care unit (ICU) admission, respectively. There is no biomarker to predict which of these patients will develop an aggressive stage that we could improve their quality of life and healthcare management. Our main goal is to include new markers for the classification of COVID-19 patients.MethodsTwo tubes of peripheral blood were collected from a total of 66 (n = 34 mild and n = 32 severe) samples (mean age 52 years). Cytometry analysis was performed using a 15-parameter panel included in the Maxpar® Human Monocyte/Macrophage Phenotyping Panel Kit. Cytometry by time-of-flight mass spectrometry (CyTOF) panel was performed in combination with genetic analysis using TaqMan® probes for ACE2 (rs2285666), MX1 (rs469390), and TMPRSS2 (rs2070788) variants. GemStone™ and OMIQ software were used for cytometry analysis.ResultsThe frequency of CD163+/CD206- population of transitional monocytes (T-Mo) was decreased in the mild group compared to that of the severe one, while T-Mo CD163-/CD206- were increased in the mild group compared to that of the severe one. In addition, we also found differences in CD11b expression in CD14dim monocytes in the severe group, with decreased levels in the female group (p = 0.0412). When comparing mild and severe disease, we also found that CD45- [p = 0.014; odds ratio (OR) = 0.286, 95% CI 0.104–0.787] and CD14dim/CD33+ (p = 0.014; OR = 0.286, 95% CI 0.104–0.787) monocytes were the best options as biomarkers to discriminate between these patient groups. CD33 was also indicated as a good biomarker for patient stratification by the analysis of GemStone™ software. Among genetic markers, we found that G carriers of TMPRSS2 (rs2070788) have an increased risk (p = 0.02; OR = 3.37, 95% CI 1.18–9.60) of severe COVID-19 compared to those with A/A genotype. This strength is further increased when combined with CD45-, T-Mo CD163+/CD206-, and C14dim/CD33+.ConclusionsHere, we report the interesting role of TMPRSS2, CD45-, CD163/CD206, and CD33 in COVID-19 aggressiveness. This strength is reinforced for aggressiveness biomarkers when TMPRSS2 and CD45-, TMPRSS2 and CD163/CD206, and TMPRSS2 and CD14dim/CD33+ are combined.

show abstract

Presepsin as a Novel Biomarker in predicting In‐hospital Mortality in Patients With COVID‐19 Pneumonia

Cited by 18 publications

References 11 publications

Predictive Values of Procalcitonin and Presepsin for Acute Kidney Injury and 30-Day Hospital Mortality in Patients with COVID-19

Predictive Values of Procalcitonin and Presepsin for Acute Kidney Injury and 30-Day Hospital Mortality in Patients with COVID-19

Potential predictors of severe course and outcome of community-acquired pneumonia

Relevance of TMPRSS2, CD163/CD206, and CD33 in clinical severity stratification of COVID-19

Contact Info

Product

Resources

About